Cure MSA

Country specific patient information


Principal investigator:
Prof. Eduardo Tolosa

Universitat de Barcelona
Hospital ClínicDepartment of Neurology
Villarroel, 170
E-08036 Barcelona

Expertise of the participating organization:

The Barcelona group has a strong clinical background in movement disorders and in particular atypical parkinsonisms. Professor Eduardo Tolosa Chief of the Neurology Service at the University Hospital is a widely recognized expert in the field and in particular in neurodegenerative disorders such as progressive supranuclear palsy and MSA. He has organized and participated in numerous symposia dedicated to this field and in clinical trials testing various pharmacological and surgical strategies in these disorders. He is the director of the University of Barcelona Brain Bank(Banco de Tejidos Neurologicos de la Universidad de Barcelona) a centre for research that is particularly devoted in the collection and investigation of brains of patients with different parkinsonian syndromes. His team has published on subjects related to parkinsonism in recognized international journals, in particularly in the field of clinical diagnostic criteria and in clinical neurophysiology. Furthermore his team is actively studying (in the Laboratory for Experimental Neurology) in animal models of parkinsonism new strategies for treatment(e.g. antiglutamergic drugs, subthalamic and pallidal lesions, etc) and cell death prevention. Genetic aspects of parkinsonsim as well as other neurodegenerative disorders is also part of the current research project of the team.

The Barcelona MSA Group besides contributing with the patient information from patients, necessary for the evaluation of the natural history part of the project, would contribute significantly to the project with the design of prospectively based clinical diagnostic criteria of MSA, through clinicopathological studies utilising the facilities of the already established University of Barcelona Brain Bank and in establishing the use of neurophysiological and genetic markers for diagnosis and/or follow-up of MSA and related disorders.

Recent publications relevant to the EMSA-SG:


Gaig C, Ezquerra M, Marti MJ, Valldeoriola F, Munoz E, Llado A, et al. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 2008.


Martinez-Rodriguez JE, Seppi K, Cardozo A, Iranzo A, Stampfer-Kountchev M, Wenning G, et al. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. Mov Disord 2007; 22: 1822-4.


Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006; 5: 572-7.


Healy DG, Abou-Sleiman PM, Ozawa T, Lees AJ, Bhatia K, Ahmadi KR, et al. A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson's disease. Ann Neurol 2004; 55: 443-6.


Iranzo A, Santamaria J, Tolosa E, Vilaseca I, Valldeoriola F, Marti MJ, et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004; 63: 930-2.


Tolosa E, Calandrella D, Gallardo M. Caribbean parkinsonism and other atypical parkinsonian disorders. Parkinsonism Relat Disord 2004; 10 Suppl 1: S19-26.


Marti MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003; 18 Suppl 6: S21-7.